|
|
继发性中枢神经系统淋巴瘤的诊疗进展
|
Abstract:
继发性中枢神经系统淋巴瘤(secondary central nervous system lymphoma, SCNSL)是一种起源于其他部位随后侵入中枢神经系统(central nervous system, CNS)的淋巴瘤亚型，其治疗方法有限，预后较差，早期诊断和干预至关重要。在本文中，我们综述了与SCNSL相关的常见临床表现、影像学特征、鉴别诊断、治疗及预后，以期为相关研究和临床实践提供参考。
Secondary central nervous system lymphoma (SCNSL) is a lymphoma subtype originating extraneurally and subsequently infiltrating the central nervous system (CNS). Treatment options are limited, and the prognosis is generally poor, making early diagnosis and intervention crucial. In this paper, we discussed the common clinical manifestations, imaging features, differential diagnoses, treatment, and prognosis associated with SCNSL, in order to provide a reference for related research and clinical practice.
| [1] | Al‐Hamadani, M., Habermann, T.M., Cerhan, J.R., Macon, W.R., Maurer, M.J. and Go, R.S. (2015) Non‐Hodgkin Lymphoma Subtype Distribution, Geodemographic Patterns, and Survival in the US: A Longitudinal Analysis of the National Cancer Data Base from 1998 to 2011. American Journal of Hematology, 90, 790-795. https://doi.org/10.1002/ajh.24086 |
| [2] | Sehn, L.H. and Salles, G. (2021) Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 384, 842-858. https://doi.org/10.1056/nejmra2027612 |
| [3] | Kakulas, B.A. and Finlay-Jones, L.R. (1962) A Lymphoma with Central Nervous System Involvement. Neurology, 12, 495-495. https://doi.org/10.1212/wnl.12.7.495 |
| [4] | Ma, J., Li, Q., Shao, J., Ma, Y., Lin, Z., Kang, H., et al. (2019) central Nervous System Involvement in Patients with Diffuse Large B Cell Lymphoma: Analysis of the Risk Factors and Prognosis from a Single-Center Retrospective Cohort Study. Cancer Management and Research, 11, 10175-10185. https://doi.org/10.2147/cmar.s225372 |
| [5] | El-Galaly, T.C., Cheah, C.Y., Bendtsen, M.D., Nowakowski, G.S., Kansara, R., Savage, K.J., et al. (2018) Treatment Strategies, Outcomes and Prognostic Factors in 291 Patients with Secondary CNS Involvement by Diffuse Large B-Cell Lymphoma. European Journal of Cancer, 93, 57-68. https://doi.org/10.1016/j.ejca.2018.01.073 |
| [6] | Simard, J. and Roschewski, M. (2022) SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 22, 709-717. https://doi.org/10.1016/j.clml.2022.06.002 |
| [7] | Thiele, B., Binder, M., Schliffke, S., Frenzel, C., Dierlamm, J., Wass, M., et al. (2021) Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation. Oncology Research and Treatment, 44, 375-381. https://doi.org/10.1159/000517531 |
| [8] | Villano, J.L., Koshy, M., Shaikh, H., Dolecek, T.A. and McCarthy, B.J. (2011) Age, Gender, and Racial Differences in Incidence and Survival in Primary CNS Lymphoma. British Journal of Cancer, 105, 1414-1418. https://doi.org/10.1038/bjc.2011.357 |
| [9] | Malikova, H., Burghardtova, M., Koubska, E., Mandys, V., Kozak, T. and Weichet, J. (2018) Secondary Central Nervous System Lymphoma: Spectrum of Morphological MRI Appearances. Neuropsychiatric Disease and Treatment, 14, 733-740. https://doi.org/10.2147/ndt.s157959 |
| [10] | Bathla, G. and Hegde, A. (2016) Lymphomatous Involvement of the Central Nervous System. Clinical Radiology, 71, 602-609. https://doi.org/10.1016/j.crad.2016.02.006 |
| [11] | Kaulen, L.D., Galluzzo, D., Hui, P., Barbiero, F., Karschnia, P., Huttner, A., et al. (2019) Prognostic Markers for Immunodeficiency-Associated Primary Central Nervous System Lymphoma. Journal of Neuro-Oncology, 144, 107-115. https://doi.org/10.1007/s11060-019-03208-w |
| [12] | Haldorsen, I.S., Espeland, A. and Larsson, E.-M. (2010) Central Nervous System Lymphoma: Characteristic Findings on Traditional and Advanced Imaging. American Journal of Neuroradiology, 32, 984-992. https://doi.org/10.3174/ajnr.a2171 |
| [13] | Villa, D., Connors, J.M., Shenkier, T.N., Gascoyne, R.D., Sehn, L.H. and Savage, K.J. (2010) Incidence and Risk Factors for Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma: The Impact of the Addition of Rituximab to CHOP Chemotherapy. Annals of Oncology, 21, 1046-1052. https://doi.org/10.1093/annonc/mdp432 |
| [14] | Gleeson, M., Counsell, N., Cunningham, D., Chadwick, N., Lawrie, A., Hawkes, E.A., et al. (2017) Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results of the UK NCRI R-CHOP-14 versus 21 Trial. Annals of Oncology, 28, 2511-2516. https://doi.org/10.1093/annonc/mdx353 |
| [15] | Appaduray, S.P., Khoo, J., Somasundaram, N., Chan, J. and Yan, S.X. (2020) Early Detection of Secondary Central Nervous System Lymphoma on PET/CT. Clinical Nuclear Medicine, 45, e254-e257. https://doi.org/10.1097/rlu.0000000000002991 |
| [16] | Bobillo, S., Khwaja, J., Ferreri, A.J. and Cwynarski, K. (2022) Prevention and Management of Secondary Central Nervous System Lymphoma. Haematologica, 108, 673-689. https://doi.org/10.3324/haematol.2022.281457 |
| [17] | Giannini, C., Dogan, A. and Salomão, D.R. (2014) CNS Lymphoma: A Practical Diagnostic Approach. Journal of Neuropathology & Experimental Neurology, 73, 478-494. https://doi.org/10.1097/nen.0000000000000076 |
| [18] | Chiavazza, C., Pellerino, A., Ferrio, F., Cistaro, A., Soffietti, R. and Rudà, R. (2018) Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring. BioMed Research International, 2018, Article ID: 3606970. https://doi.org/10.1155/2018/3606970 |
| [19] | Law, M., Yang, S., Wang, H., et al. (2003) Glioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imaging and Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging. AJNR American Journal of Neuroradiology, 24, 1989-1998. |
| [20] | Calli, C., Kitis, O., Yunten, N., Yurtseven, T., Islekel, S. and Akalin, T. (2006) Perfusion and Diffusion MR Imaging in Enhancing Malignant Cerebral Tumors. European Journal of Radiology, 58, 394-403. https://doi.org/10.1016/j.ejrad.2005.12.032 |
| [21] | Faehndrich, J., Weidauer, S., Pilatus, U., Oszvald, A., Zanella, F.E. and Hattingen, E. (2011) Neuroradiological Viewpoint on the Diagnostics of Space-Occupying Brain Lesions. Clinical Neuroradiology, 21, 123-139. https://doi.org/10.1007/s00062-011-0073-6 |
| [22] | Hwang, T., Close, T.P., Grego, J.M., Brannon, W.L. and Gonzales, F. (1996) Predilection of Brain Metastasis in Gray and White Matter Junction and Vascular Border Zones. Cancer, 77, 1551-1555. https://doi.org/10.1002/(sici)1097-0142(19960415)77:8<1551::aid-cncr19>3.0.co;2-z |
| [23] | Fink, K. and Fink, J. (2013) Imaging of Brain Metastases. Surgical Neurology International, 4, S209-S219. https://doi.org/10.4103/2152-7806.111298 |
| [24] | Starr, C.J. and Cha, S. (2017) Meningioma Mimics: Five Key Imaging Features to Differentiate Them from Meningiomas. Clinical Radiology, 72, 722-728. https://doi.org/10.1016/j.crad.2017.05.002 |
| [25] | Hardy, T.A. and Chataway, J. (2013) Tumefactive Demyelination: An Approach to Diagnosis and Management. Journal of Neurology, Neurosurgery & Psychiatry, 84, 1047-1053. https://doi.org/10.1136/jnnp-2012-304498 |
| [26] | Altintas, A., Petek, B., Isik, N., Terzi, M., Bolukbasi, F., Tavsanli, M., et al. (2012) Clinical and Radiological Characteristics of Tumefactive Demyelinating Lesions: Follow-Up Study. Multiple Sclerosis Journal, 18, 1448-1453. https://doi.org/10.1177/1352458512438237 |
| [27] | Sánchez, P., Chan, F. and Hardy, T.A. (2021) Tumefactive Demyelination: Updated Perspectives on Diagnosis and Management. Expert Review of Neurotherapeutics, 21, 1005-1017. https://doi.org/10.1080/14737175.2021.1971077 |
| [28] | Bernardini, G.L. (2004) Diagnosis and Management of Brain Abscess and Subdural Empyema. Current Neurology and Neuroscience Reports, 4, 448-456. https://doi.org/10.1007/s11910-004-0067-8 |
| [29] | Muccio, C.F., Caranci, F., D’Arco, F., Cerase, A., De Lipsis, L., Esposito, G., et al. (2014) Magnetic Resonance Features of Pyogenic Brain Abscesses and Differential Diagnosis Using Morphological and Functional Imaging Studies: A Pictorial Essay. Journal of Neuroradiology, 41, 153-167. https://doi.org/10.1016/j.neurad.2014.05.004 |
| [30] | Baraniskin, A., Deckert, M., Schulte‐Altedorneburg, G., Schlegel, U. and Schroers, R. (2011) Current Strategies in the Diagnosis of Diffuse Large B‐Cell Lymphoma of the Central Nervous System. British Journal of Haematology, 156, 421-432. https://doi.org/10.1111/j.1365-2141.2011.08928.x |
| [31] | Provenzale, J.M., Joseph, G.J. and Barboriak, D.P. (1998) Dural Sinus Thrombosis: Findings on CT and MR Imaging and Diagnostic Pitfalls. American Journal of Roentgenology, 170, 777-783. https://doi.org/10.2214/ajr.170.3.9490973 |
| [32] | Li, L., Leung, G.K., Ho, R.S. and Lui, W. (2015) Recurrent Natural Killer Cell Lymphoma with Central Nervous System Metastasis Mimicking Cerebellar Infarction. World Neurosurgery, 84, 2074.e5-2074.e9. https://doi.org/10.1016/j.wneu.2015.06.076 |
| [33] | Greschus, S., Kuchelmeister, K., Oeynhausen, S., Fischer, H.P. and Urbach, H. (2013) Cerebral Tuberculoma Mimicking Brain Tumor. Clinical Neuroradiology, 24, 389-393. https://doi.org/10.1007/s00062-013-0258-2 |
| [34] | Khatri, G.D., Krishnan, V., Antil, N. and Saigal, G. (2018) Magnetic Resonance Imaging Spectrum of Intracranial Tubercular Lesions: One Disease, Many Faces. Polish Journal of Radiology, 83, 628-639. https://doi.org/10.5114/pjr.2018.81408 |
| [35] | DeLance, A.R., Safaee, M., Oh, M.C., Clark, A.J., Kaur, G., Sun, M.Z., et al. (2013) Tuberculoma of the Central Nervous System. Journal of Clinical Neuroscience, 20, 1333-1341. https://doi.org/10.1016/j.jocn.2013.01.008 |
| [36] | Liu, Z., Wen, G., Huang, Y., Dong, Y., Wang, Z., Alhaskawi, A., et al. (2023) [18F]AlF-NOTA-ADH-1: A New PET Molecular Radiotracer for Imaging of N-Cadherin-Positive Tumors. Frontiers in Oncology, 13, Article ID: 1126721. https://doi.org/10.3389/fonc.2023.1126721 |
| [37] | Iancu, S.D., Albu, C., Chiriac, L., Moldovan, R., Stefancu, A., Moisoiu, V., et al. (2020) Assessment of Gold-Coated Iron Oxide Nanoparticles as Negative T2 Contrast Agent in Small Animal MRI Studies. International Journal of Nanomedicine, 15, 4811-4824. https://doi.org/10.2147/ijn.s253184 |
| [38] | Marzola, P., Busato, A., Bonafede, R., Bontempi, P., Scambi, I., Schiaffino, L., et al. (2016) Magnetic Resonance Imaging of Ultrasmall Superparamagnetic Iron Oxide-Labeled Exosomes from Stem Cells: A New Method to Obtain Labeled Exosomes. International Journal of Nanomedicine, 11, 2481-2490. https://doi.org/10.2147/ijn.s104152 |
| [39] | Lohmann, P., Werner, J., Shah, N.J., Fink, G.R., Langen, K. and Galldiks, N. (2019) Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients. Cancers, 11, Article No. 153. https://doi.org/10.3390/cancers11020153 |
| [40] | Shah, T. and Venur, V.A. (2023) Central Nervous System Lymphoma. Seminars in Neurology, 43, 825-832. https://doi.org/10.1055/s-0043-1776783 |
| [41] | Ghose, A., Elias, H.K., Guha, G., Yellu, M., Kundu, R. and Latif, T. (2015) Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis—A Systematic Review of Prospective Studies. Clinical Lymphoma Myeloma and Leukemia, 15, 451-457. https://doi.org/10.1016/j.clml.2015.02.026 |
| [42] | Savage, K.J., Slack, G.W., Mottok, A., Sehn, L.H., Villa, D., Kansara, R., et al. (2016) Impact of Dual Expression of MYC and BCL2 by Immunohistochemistry on the Risk of CNS Relapse in DLBCL. Blood, 127, 2182-2188. https://doi.org/10.1182/blood-2015-10-676700 |
| [43] | El-Galaly, T.C., Villa, D., Michaelsen, T.Y., Hutchings, M., Mikhaeel, N.G., Savage, K.J., et al. (2017) The Number of Extranodal Sites Assessed by PET/CT Scan Is a Powerful Predictor of CNS Relapse for Patients with Diffuse Large B-Cell Lymphoma: An International Multicenter Study of 1532 Patients Treated with Chemoimmunotherapy. European Journal of Cancer, 75, 195-203. https://doi.org/10.1016/j.ejca.2016.12.029 |
| [44] | Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L.H., et al. (2016) CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chop. Journal of Clinical Oncology, 34, 3150-3156. https://doi.org/10.1200/jco.2015.65.6520 |
| [45] | Peñalver, F., Sancho, J., de la Fuente, A., Olave, M., Martín, A., Panizo, C., et al. (2016) Guidelines for Diagnosis, Prevention and Management of Central Nervous System Involvement in Diffuse Large B-Cell Lymphoma Patients by the Spanish Lymphoma Group (Geltamo). Haematologica, 102, 235-245. https://doi.org/10.3324/haematol.2016.149120 |
| [46] | Cox, M.C., Di Napoli, A., Scarpino, S., Salerno, G., Tatarelli, C., Talerico, C., et al. (2014) Clinicopathologic Characterization of Diffuse-Large-B-Cell Lymphoma with an Associated Serum Monoclonal IGM Component. PLOS ONE, 9, e93903. https://doi.org/10.1371/journal.pone.0093903 |
| [47] | Krsmanovic, P., Mocikova, H., Chramostova, K., Klanova, M., Trnkova, M., Pesta, M., et al. (2022) Circulating MicroRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas. Cancers, 14, Article No. 2305. https://doi.org/10.3390/cancers14092305 |
| [48] | Hiemcke‐Jiwa, L.S., Minnema, M.C., Radersma‐van Loon, J.H., Jiwa, N.M., de Boer, M., Leguit, R.J., et al. (2017) The Use of Droplet Digital PCR in Liquid Biopsies: A Highly Sensitive Technique for MYD88 p.(L265P) Detection in Cerebrospinal Fluid. Hematological Oncology, 36, 429-435. https://doi.org/10.1002/hon.2489 |
| [49] | Savage, K.J. (2017) Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma: Defining High-Risk Patients and Optimization of Prophylaxis Strategies. Hematology, 2017, 578-586. https://doi.org/10.1182/asheducation-2017.1.578 |
| [50] | Puckrin, R., El Darsa, H., Ghosh, S., Peters, A., Owen, C. and Stewart, D. (2021) Ineffectiveness of High‐Dose Methotrexate for Prevention of CNS Relapse in Diffuse Large B‐Cell Lymphoma. American Journal of Hematology, 96, 764-771. https://doi.org/10.1002/ajh.26181 |
| [51] | Orellana-Noia, V.M., Reed, D.R., McCook, A.A., Sen, J.M., Barlow, C.M., Malecek, M., et al. (2022) Single-Route CNS Prophylaxis for Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes from 21 US Academic Institutions. Blood, 139, 413-423. https://doi.org/10.1182/blood.2021012888 |
| [52] | Lewis, K.L., Chin, C.K., Manos, K., Casey, J., Hamad, N., Crawford, J., et al. (2020) Ibrutinib for Central Nervous System Lymphoma: The Australasian Lymphoma Alliance/MD Anderson Cancer Center Experience. British Journal of Haematology, 192, 1049-1053. https://doi.org/10.1111/bjh.16946 |
| [53] | Ayed, A.O., Chiappella, A., Pederson, L., Laplant, B.R., Congiu, A.G., Gaidano, G., et al. (2018) CNS Relapse in Patients with DLBCL Treated with Lenalidomide Plus R-CHOP (R2CHOP): Analysis from Two Phase 2 Studies. Blood Cancer Journal, 8, Article No. 63. https://doi.org/10.1038/s41408-018-0097-0 |
| [54] | Perry, C., Ben Barouch, S., Goldschmidt, N., Sarid, N., Herishanu, Y., Shvidel, L., et al. (2019) Characteristics, Management and Outcome of DLBCL Patients, Presenting with Simultaneous Systemic and CNS Disease at Diagnosis: A Retrospective Multicenter Study. American Journal of Hematology, 94, 992-1001. https://doi.org/10.1002/ajh.25558 |
